Clinical Trial: Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial.

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06837129) titled 'Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial.' on Feb. 16.

Brief Summary: We study efficacy of iv nalbuphine in prevention of intrathecal morphine-induced nausea and vomiting in patients undergoing cesarean section.

Study Start Date: Oct. 01, 2023

Study Type: INTERVENTIONAL

Condition: Intrathecal Morphine Caesarean Section Postoperative Nausea and Vomiting Neuraxial Opioid

Intervention: DRUG: A single dose of 4 mg iv nalbuphine

prevention of nausea vomiting

Recruitment Status: ACTIVE_NOT_RECRUITIN...